Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

The Gly82Ser Polymorphism of the Receptor of Advanced Glycation End Product (RAGE) Gene Is Not Associated With Type 1 or Type 2 Diabetes in a Brazilian Population

  1. Carolina L. Naka, BSC,
  2. Geraldo Picheth, MSC,
  3. Vânia Manfredini Alcântera, PHD,
  4. Rosangela R. Réa, MD,
  5. Eleidi A. Chautard-Freire-Maia, PHD,
  6. Fábio de Oliveira Pedrosa, PHD,
  7. Tania Leme da Rocha Martinez, PHD and
  8. Emanuel M. Souza, PHD
  1. Department of Biochemistry and Molecular Biology, Federal University of Parana, Curitiba-PR, Brazil
  1. Address correspondence and reprint requests to Geraldo Picheth, MsC, Department of Biochemistry and Molecular Biology, Federal University of Parana, 81531990, P.O. Box 19046, Curitiba-PR, Brazil. E-mail: gpicheth{at}ufpr.br
Diabetes Care 2006 Mar; 29(3): 712-713. https://doi.org/10.2337/diacare.29.03.06.dc05-1817
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading
  • AGE, advanced glycation end products
  • RAGE, receptor for AGE

In diabetes, the levels of advanced glycation end products (AGEs) increase as a result of chronic hyperglycemia (1). The best-characterized receptor for AGEs is RAGE. The AGE-RAGE interaction mediates activation and secretion of various cytokines via activation of factors such as the nuclear factor-κB, leading to a proinflammatory process (1). A guanine-to-adenine single nucleotide polymorphism at codon 82 (GGC→AGC) located in exon 3 of RAGE causes the amino acid change glycine to serine (Gly82Ser or G82S polymorphism) within the putative ligand-binding domain of the protein (2). The RAGE Ser82 isoform has been suggested to upregulate the inflammatory response upon engagement of S100/calgranulins, thereby contributing to the enhancement of proinflammatory mechanisms (3). The aim of this study was to investigate the association of the RAGE polymorphism Gly82Ser with type 1 and type 2 diabetes in a Brazilian population compared with a nondiabetic sample.

RESEARCH DESIGN AND METHODS

The ethnic composition of this unrelated sample was 65.4% Euro Brazilian, 33.8% African Brazilian, and 0.8% Asians. The American Diabetes Association criteria for diabetes diagnosis were used. Genotyping was performed by PCR–restriction fragment–length polymorphism using the AluI (AG↓CT) restriction enzyme; the DNA fragments were separated by 10% polyacrylamide (29:1) gel electrophoresis and stained with ethidium bromide. The DNA was then visualized under ultraviolet light and the images captured by a charge-coupled device camera (Biochemi System; UVP). Primers and PCR conditions were as described (2,4). Our university committee for ethics in human research approved this study. We analyzed 82 nondiabetic subjects (38 men and 44 women, aged 58.2 ± 10.1 years, and HbA1c [A1C] 5.2 ± 0.65%), 105 type 1 diabetic patients (41 men and 64 women, aged 24.3 ± 7.1 years, A1C 9.9 ± 2.4%), and 147 type 2 diabetic patients (50 men and 97 women, aged 55.1 ± 11.4 years, A1C 8.7 ± 2.1%).

RESULTS

Nonproliferative diabetic retinopathy was found in 15.4% of the diabetic patients and proliferative retinopathy in 12.4%. Furthermore, 0.9% of the diabetic patients had macrovascular disease, 19.6% had microalbuminuria, and 18.2% had either macroalbuminuria or overt renal insufficiency. We found two genotypes in the population studied: homogyzotes for the Gly82 isoform of RAGE (GG) and heterozygotes Gly82/Ser82 (GS). There were no differences (P > 0.05; two-tailed Fisher’s exact test) in the genotype frequencies (96.3% GG, 3.7% GS for nondiabetic subjects vs. 98.1% GG, 1.9% GS for type 1 diabetic subjects and 97.9% GG, 2.1% GS for type 2 diabetic subjects). No homozygote for the Ser82 isoform (SS) was detected. Of eight individuals with the GS genotype detected in all groups, seven (three nondiabetic, two type 2 diabetic, and two type 1 diabetic subjects) were found among the Euro Brazilians and one (type 2 diabetic) among Asians. The Gly82Ser polymorphism was not found in the African-Brazilian population. Further investigation of the frequency of this polymorphism in African Brazilians must be conducted to clarify the significance of this finding. The genotype frequency of the Gly82Ser polymorphism in this Brazilian population is similar (P > 0.05) to that found in Asian nondiabetic subjects (10%) (2), Caucasian-English type 2 diabetic subjects (7%) (2), Asian-Indian nondiabetic subjects (2%) and type 2 diabetic subjects with retinopathy (7%) (5), Finnish nondiabetic subjects (7%) (6), Caucasian- Czech nondiabetic subjects (0.7%) (4), American-Caucasian nondiabetic subjects (6.9%) and type 2 diabetic subjects (7.9%) (7), and Caucasian-Danish type 1 diabetic subjects with nephropathy (5.9%) (8). However, the frequencies found in this study were significantly lower (P < 0.05) when compared with Chinese nondiabetic (40.4%) and type 2 diabetic (32.3%) subjects (9), Japanese nondiabetic (34.6%) and type 2 diabetic (21.6%) subjects (10), Finnish subjects with coronary heart disease with or without type 2 diabetes (12 and 15%, respectively) (6), Asian-Indian type 2 diabetic subjects without retinopathy (18%) (5), the nondiabetic Caucasian-English population (12%) (2), and Caucasian-Danish type 1 diabetic subjects without nephropathy (9.4%) (8). We found no association of the GS genotype with diabetes complications. However, the lack of clear association of the RAGE polymorphism with diabetes complications may be due to the low frequencies observed in all groups studied.

CONCLUSIONS

In conclusion, our data indicate that the Gly82Ser polymorphism of the RAGE gene is not associated with either type 1 or type 2 diabetes in a Brazilian sample, suggesting that this single nucleotide polymorphism may not be associated with development of the disease in this population. Furthermore, our results suggest a very low frequency of the Gly82Ser polymorphism in the African-Brazilian population. This is the first frequency study of the Gly82Ser RAGE polymorphism in a Brazilian population.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 20, 2005.
    • Received September 27, 2005.
  • DIABETES CARE

References

  1. ↵
    Hudson BI, Hofmann MA, Bucciarelli L, Wendt T, Moser B, Lu Y, Qu W, Stern DM, D’Agati V, Yan SD, Yan SF, Grant PJ, Schmidt AM: Glycation and diabetes: the RAGE connection. Curr Sci 83: 1515–1521, 2002
    OpenUrl
  2. ↵
    Hudson BI, Stickland MH, Grant PJ: Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 47: 1155–1157, 1998
    OpenUrlPubMedWeb of Science
  3. ↵
    Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123–135, 2002
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Kanková K, Záhejský J, Márová I, Muzik J, Kuhrová V, Blazková M, Znojil V, Beránek M, Vácha J: Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDD. J Diabetes Complications 15: 185–192, 2001
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T: Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II Asian Indian patients. J Diabetes Complications 16: 391–394, 2002
    OpenUrlCrossRefPubMed
  6. ↵
    Pulkkinen A, Viitanen L, Kareinen A, Letho S, Laakso M: Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes (Letter). Diabetes Care 23: 864, 2000
    OpenUrlPubMed
  7. ↵
    Hofmann MA, Yang Q, Harja E, Kedia P, Gregersen PK, Cupples LA, Schmidt AM, Hudson BI: The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham Offspring Study. Atherosclerosis 182: 301–305, 2005
    OpenUrlPubMed
  8. ↵
    Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving H-H, Cambien F: Polymorphism screening of four genes encoding advanced glycation end-product putative receptors: association study with nephropathy in type 1 diabetic patients. Diabetes 50: 1214–1218, 2001
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Liu L, Xiang K: RAGE Gly82Ser polymorphism in diabetic microangiopathy (Letter). Diabetes Care 22: 646, 1999
    OpenUrlCrossRefPubMed
  10. ↵
    Yoshioka K, Yoshida T, Takakura Y, Umekawa T, Kogure A, Toda H, Yoshikawa T: Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients. Intern Med 44: 417–421, 2005
    OpenUrlPubMed
PreviousNext
Back to top
Diabetes Care: 29 (3)

In this Issue

March 2006, 29(3)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Gly82Ser Polymorphism of the Receptor of Advanced Glycation End Product (RAGE) Gene Is Not Associated With Type 1 or Type 2 Diabetes in a Brazilian Population
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Gly82Ser Polymorphism of the Receptor of Advanced Glycation End Product (RAGE) Gene Is Not Associated With Type 1 or Type 2 Diabetes in a Brazilian Population
Carolina L. Naka, Geraldo Picheth, Vânia Manfredini Alcântera, Rosangela R. Réa, Eleidi A. Chautard-Freire-Maia, Fábio de Oliveira Pedrosa, Tania Leme da Rocha Martinez, Emanuel M. Souza
Diabetes Care Mar 2006, 29 (3) 712-713; DOI: 10.2337/diacare.29.03.06.dc05-1817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Gly82Ser Polymorphism of the Receptor of Advanced Glycation End Product (RAGE) Gene Is Not Associated With Type 1 or Type 2 Diabetes in a Brazilian Population
Carolina L. Naka, Geraldo Picheth, Vânia Manfredini Alcântera, Rosangela R. Réa, Eleidi A. Chautard-Freire-Maia, Fábio de Oliveira Pedrosa, Tania Leme da Rocha Martinez, Emanuel M. Souza
Diabetes Care Mar 2006, 29 (3) 712-713; DOI: 10.2337/diacare.29.03.06.dc05-1817
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
  • Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
  • Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.